Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker.

Most cases of pancreatic cancer are not diagnosed until they are no longer curable with surgery. Therefore, it is critical to develop a sensitive, preferably noninvasive, method for detecting the disease at an earlier stage. In order to identify biomarkers for pancreatic cancer, we devised an in vitro positive/negative selection strategy to identify RNA ligands (aptamers) that could detect structural differences between the secretomes of pancreatic cancer and non-cancerous cells. Using this molecular recognition approach, we identified an aptamer (M9-5) that differentially bound conditioned media from cancerous and non-cancerous human pancreatic cell lines. This aptamer further discriminated between the sera of pancreatic cancer patients and healthy volunteers with high sensitivity and specificity. We utilized biochemical purification methods and mass-spectrometric analysis to identify the M9-5 target as cyclophilin B (CypB). This molecular recognition-based strategy simultaneously identified CypB as a serum biomarker and generated a new reagent to recognize it in body fluids. Moreover, this approach should be generalizable to other diseases and complementary to traditional approaches that focus on differences in expression level between samples. Finally, we suggest that the aptamer we identified has the potential to serve as a tool for the early detection of pancreatic cancer.

[1]  Ying-Fon Chang,et al.  Tenascin-C Aptamers Are Generated Using Tumor Cells and Purified Protein* , 2001, The Journal of Biological Chemistry.

[2]  B. Sullenger,et al.  Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. , 2007, Oligonucleotides.

[3]  M. Tsao,et al.  Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. , 1996, The American journal of pathology.

[4]  Stephen A. Williams,et al.  Unlocking Biomarker Discovery: Large Scale Application of Aptamer Proteomic Technology for Early Detection of Lung Cancer , 2010, PloS one.

[5]  M. Nakao,et al.  A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. , 1999, Journal of immunology.

[6]  Tracy R. Keeney,et al.  Aptamer-based multiplexed proteomic technology for biomarker discovery , 2010, Nature Precedings.

[7]  M. Oka,et al.  Peptidomics-based approach reveals the secretion of the 29-residue COOH-terminal fragment of the putative tumor suppressor protein DMBT1 from pancreatic adenocarcinoma cell lines. , 2002, Cancer research.

[8]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, , 2006 .

[9]  Qun Huo,et al.  Protein complexes/aggregates as potential cancer biomarkers revealed by a nanoparticle aggregation immunoassay. , 2010, Colloids and surfaces. B, Biointerfaces.

[10]  D. Shangguan,et al.  Aptamers evolved from live cells as effective molecular probes for cancer study , 2006, Proceedings of the National Academy of Sciences.

[11]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[12]  A. Siriwardena,et al.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[13]  S. Hanash,et al.  Mining the plasma proteome for cancer biomarkers , 2008, Nature.

[14]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[15]  M. Godbout,et al.  An endoplasmic reticulum-specific cyclophilin , 1991, Molecular and cellular biology.

[16]  L. Kay,et al.  Correlation between dynamics and high affinity binding in an SH2 domain interaction. , 1996, Biochemistry.

[17]  T. Lohman,et al.  A double-filter method for nitrocellulose-filter binding: application to protein-nucleic acid interactions. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[18]  B. Sullenger,et al.  In vivo selection of tumor-targeting RNA motifs , 2009, Nature chemical biology.

[19]  J. Nevins,et al.  Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function , 1996, Nature Medicine.

[20]  Troels Z. Kristiansen,et al.  Biomarker Discovery from Pancreatic Cancer Secretome Using a Differential Proteomic Approach*S , 2006, Molecular & Cellular Proteomics.

[21]  Xiaohong Fang,et al.  Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. , 2010, Accounts of chemical research.

[22]  M. Tempero,et al.  Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. , 1987, Cancer research.

[23]  J. Kay.  Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. , 1996, The Biochemical journal.

[24]  Weihong Tan,et al.  DNA Aptamers as Molecular Probes for Colorectal Cancer Study , 2010, PloS one.

[25]  Masao Honda,et al.  Comparative analysis of various tumor‐associated antigen‐specific t‐cell responses in patients with hepatocellular carcinoma , 2011, Hepatology.

[26]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[27]  W. Park,et al.  Role of cyclophilin B in tumorigenesis and cisplatin resistance in hepatocellular carcinoma in humans , 2011, Hepatology.

[28]  M. Schrader,et al.  Analysis of low abundance membrane-associated proteins from rat pancreatic zymogen granules. , 2010, Journal of proteome research.

[29]  A. Koong,et al.  Pancreatic tumors show high levels of hypoxia. , 2000, International journal of radiation oncology, biology, physics.

[30]  Paul J. Hatala,et al.  In Vitro Selection Using Modified or Unnatural Nucleotides , 2001, Current protocols in nucleic acid chemistry.

[31]  R. Corn,et al.  Detection of protein biomarkers using RNA aptamer microarrays and enzymatically amplified surface plasmon resonance imaging. , 2007, Analytical chemistry.

[32]  A. Pardi,et al.  High-resolution molecular discrimination by RNA. , 1994, Science.

[33]  D. Shangguan,et al.  Aptamer Directly Evolved from Live Cells Recognizes Membrane Bound Immunoglobin Heavy Mu Chain in Burkitt's Lymphoma Cells*S , 2007, Molecular & Cellular Proteomics.

[34]  Simon M. Lin,et al.  Expression of cyclophilin B is associated with malignant progression and regulation of genes implicated in the pathogenesis of breast cancer. , 2009, The American journal of pathology.

[35]  S. Gygi,et al.  Purification and Identification of Secreted Oxidative Stress-induced Factors from Vascular Smooth Muscle Cells* , 2000, The Journal of Biological Chemistry.

[36]  B. Haendler,et al.  A novel secreted cyclophilin-like protein (SCYLP). , 1991, The Journal of biological chemistry.

[37]  A. Vlahou,et al.  Secretome proteomics for discovery of cancer biomarkers. , 2010, Journal of proteomics.

[38]  C. Walsh,et al.  Human cyclophilin B: a second cyclophilin gene encodes a peptidyl-prolyl isomerase with a signal sequence. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Scarpa,et al.  Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  A. Barrett,et al.  Selection of Thioaptamers for Diagnostics and Therapeutics , 2006, Annals of the New York Academy of Sciences.

[41]  P. Coffer,et al.  Induction of prosurvival molecules by apoptotic stimuli: involvement of FOXO3a and ROS , 2005, Oncogene.

[42]  M. Tsao,et al.  Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. , 2000, The American journal of pathology.

[43]  M. Sporn,et al.  Synthetic Triterpenoids Prolong Survival in a Transgenic Mouse Model of Pancreatic Cancer , 2010, Cancer Prevention Research.